POST-CABGDM: Empagliflozin in Perioperative CABG

Sponsor
University of Sao Paulo General Hospital
Study ID
NCT04523064
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin 25 MG — DRUG
    Patients with diabetes waiting for surgery will receive empagliflozin for at least three months.

Study Details

Introduction: Diabetes Mellitus (DM) is a condition known to be associated with coronary artery disease (CAD) and its role as promoter of atherosclerosis is well stablished. The revascularization surgery is commonly indicated to patients with multivessel coronary disease and kidney injury is a prevalent complication in post operation. This work aims to evaluate the impact of a strategy to control Diabetes Mellitus using inhibitors of sodium-glucose cotransporters (ISGLT2) in diabetics patients with assigned myocardial revascularization with cardiopulmonary bypass

Key Dates

Start date
Sep 22, 2020
Status verified
Jun 2024
Primary completion
Jan 30, 2024
Completion
Jan 30, 2024

Study Design

Enrollment
155 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: SGLT2i (empagliflozin)
    Empagliflozin 25 mg 1 time day for three months
  • No Intervention: Standard of care
    Standard care treatment of diabetes patients in our center

Primary Outcome Measure

Acute kidney injury [ Time Frame: 3 months ]

Related Studies